A detailed history of Ubs Group Ag transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Ubs Group Ag holds 604,152 shares of ACAD stock, worth $10.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
604,152
Previous 455,551 32.62%
Holding current value
$10.2 Million
Previous $7.4 Million 25.6%
% of portfolio
0.0%
Previous 0.0%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$15.14 - $19.14 $2.25 Million - $2.84 Million
148,601 Added 32.62%
604,152 $9.3 Million
Q2 2024

Aug 13, 2024

BUY
$14.62 - $18.42 $1.63 Million - $2.06 Million
111,670 Added 32.47%
455,551 $7.4 Million
Q1 2024

May 13, 2024

BUY
$17.79 - $30.86 $649,726 - $1.13 Million
36,522 Added 11.88%
343,881 $6.36 Million
Q4 2023

Feb 09, 2024

BUY
$20.78 - $31.77 $3.38 Million - $5.17 Million
162,663 Added 112.42%
307,359 $9.62 Million
Q3 2023

Nov 09, 2023

BUY
$20.84 - $33.47 $104,095 - $167,182
4,995 Added 3.58%
144,696 $3.02 Million
Q2 2023

Aug 11, 2023

SELL
$17.8 - $25.65 $240,122 - $346,018
-13,490 Reduced 8.81%
139,701 $3.35 Million
Q1 2023

May 12, 2023

SELL
$16.32 - $20.92 $3.49 Million - $4.48 Million
-214,128 Reduced 58.29%
153,191 $2.88 Million
Q4 2022

Feb 08, 2023

BUY
$14.2 - $18.63 $4.49 Million - $5.89 Million
316,246 Added 619.2%
367,319 $5.85 Million
Q3 2022

Nov 10, 2022

BUY
$14.11 - $18.27 $243,693 - $315,541
17,271 Added 51.09%
51,073 $835,000
Q2 2022

Aug 10, 2022

SELL
$13.01 - $27.22 $385,499 - $806,555
-29,631 Reduced 46.71%
33,802 $477,000
Q1 2022

May 16, 2022

SELL
$20.94 - $27.5 $3.26 Million - $4.28 Million
-155,475 Reduced 71.02%
63,433 $1.54 Million
Q4 2021

Feb 14, 2022

BUY
$16.79 - $27.09 $23,589 - $38,061
1,405 Added 0.65%
218,908 $5.11 Million
Q3 2021

Nov 15, 2021

BUY
$15.78 - $24.77 $3.25 Million - $5.09 Million
205,648 Added 1734.69%
217,503 $3.61 Million
Q2 2021

Aug 13, 2021

SELL
$19.4 - $27.42 $292,552 - $413,493
-15,080 Reduced 55.99%
11,855 $289,000
Q1 2021

May 12, 2021

SELL
$25.02 - $54.99 $293,384 - $644,812
-11,726 Reduced 30.33%
26,935 $695,000
Q4 2020

Feb 11, 2021

BUY
$41.04 - $56.79 $339,934 - $470,391
8,283 Added 27.27%
38,661 $2.07 Million
Q3 2020

Nov 12, 2020

BUY
$36.42 - $57.0 $216,735 - $339,207
5,951 Added 24.36%
30,378 $1.25 Million
Q2 2020

Jul 31, 2020

BUY
$39.26 - $52.73 $16,567 - $22,252
422 Added 1.76%
24,427 $1.18 Million
Q1 2020

May 01, 2020

SELL
$31.65 - $46.87 $3.66 Million - $5.42 Million
-115,667 Reduced 82.81%
24,005 $1.01 Million
Q4 2019

Feb 14, 2020

BUY
$36.21 - $51.4 $733,252 - $1.04 Million
20,250 Added 16.96%
139,672 $5.98 Million
Q3 2019

Nov 14, 2019

BUY
$22.22 - $44.01 $1.35 Million - $2.67 Million
60,565 Added 102.9%
119,422 $4.3 Million
Q2 2019

Aug 14, 2019

SELL
$23.32 - $28.12 $469,898 - $566,618
-20,150 Reduced 25.5%
58,857 $1.57 Million
Q1 2019

May 14, 2019

SELL
$16.17 - $27.38 $3.67 Million - $6.21 Million
-226,807 Reduced 74.17%
79,007 $2.12 Million
Q4 2018

Feb 14, 2019

SELL
$14.32 - $22.92 $55,275 - $88,471
-3,860 Reduced 1.25%
305,814 $4.95 Million
Q3 2018

Nov 14, 2018

BUY
$13.03 - $21.81 $1.72 Million - $2.88 Million
131,931 Added 74.23%
309,674 $6.43 Million
Q2 2018

Aug 14, 2018

SELL
$15.07 - $22.34 $3.94 Million - $5.84 Million
-261,344 Reduced 59.52%
177,743 $2.71 Million
Q1 2018

May 15, 2018

BUY
$22.47 - $32.33 $4.98 Million - $7.16 Million
221,465 Added 101.77%
439,087 $9.87 Million
Q4 2017

Feb 14, 2018

SELL
$26.84 - $39.14 $945,116 - $1.38 Million
-35,213 Reduced 13.93%
217,622 $6.55 Million
Q3 2017

Nov 14, 2017

BUY
$29.49 - $38.37 $234,592 - $305,233
7,955 Added 3.25%
252,835 $9.52 Million
Q2 2017

Aug 14, 2017

BUY
N/A
165,503 Added 208.5%
244,880 $6.83 Million
Q1 2017

Nov 14, 2017

BUY
N/A
79,377
79,377 $2.73 Million

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.73B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.